Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company (NASDAQ: STAA) features prominently in ophthalmic and corporate news due to its focus on implantable intraocular lenses and its role in the vision correction market. Company press releases describe STAAR as the global leader in implantable phakic intraocular lenses, particularly through the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, and as a long-standing participant in ophthalmic surgery since 1982.
This news page aggregates coverage related to STAAR’s product developments, strategic decisions, shareholder actions, and governance changes. Recent announcements include the proposed and later terminated merger agreement with Alcon, a series of special meetings and proxy solicitations, and a cooperation agreement with major shareholder Broadwood Partners under which representatives of Broadwood and Yunqi Capital joined STAAR’s Board of Directors. These events illustrate how transaction activity and shareholder perspectives can influence the company’s direction while it continues to operate as a standalone, publicly traded company on Nasdaq.
Readers can expect updates on topics such as merger and acquisition proposals, outcomes of shareholder votes, board appointments, and other material events reported in STAAR’s press releases and related communications. Because STAAR’s core business centers on ophthalmic surgical products like Implantable Collamer Lenses and intraocular lenses, news may also highlight the positioning of its EVO ICL technology and its use in vision correction procedures in markets around the world.
For investors, analysts, and industry observers, following STAA news offers insight into both the company’s ophthalmic product strategy and its evolving governance and ownership dynamics. This page provides a centralized view of those developments as they are reported in official company and market communications.
STAAR Surgical (NASDAQ: STAA), a global leader in phakic IOLs, has reaffirmed the value of its merger agreement with Alcon. The deal offers shareholders $28 per share in cash, representing a 51% premium to STAAR's closing price on August 4, 2025, and a 59% premium to its 90-day VWAP.
The company emphasizes that this valuation exceeds potential standalone performance, particularly given STAAR's declining growth rate and challenges in key markets, especially China. The Board of Directors unanimously supports the merger, citing it as the best interest for all stockholders. STAAR has filed preliminary proxy materials with the SEC regarding the proposed transaction.
STAAR Surgical (NASDAQ: STAA) reported challenging Q2 2025 results, with net sales declining 55% year-over-year to $44.3 million, primarily due to planned inventory reduction in China. Excluding China, sales grew 10% to $39.0 million.
The company reported a net loss of $(16.8) million, or $(0.34) per share, compared to net income of $7.4 million year ago. Gross margin decreased to 74.0% from 79.2% last year but improved from 65.8% in Q1 2025. The company maintained a strong balance sheet with $189.9 million in cash and investments, with no debt.
During Q2, STAAR repurchased 261,000 shares for approximately $4.5 million under its $30 million share repurchase program. The company is currently pending acquisition by Alcon Inc.
Alcon (SIX/NYSE: ALC) has entered into a definitive merger agreement to acquire STAAR Surgical (NASDAQ: STAA) for $28 per share in cash, representing a total equity value of approximately $1.5 billion. The deal offers a 59% premium to STAAR's 90-day VWAP.
The acquisition includes STAAR's EVO family of Implantable Collamer® Lenses (ICL), which provides vision correction for moderate to high myopia patients. This strategic move enhances Alcon's surgical vision correction portfolio, particularly targeting the growing myopia market, expected to affect 50% of the world's population by 2050.
The transaction is expected to close within 6-12 months, subject to regulatory and STAAR shareholder approval, and become earnings accretive in year two. Alcon plans to finance the acquisition through short- and long-term credit facilities.
STAAR Surgical (NASDAQ: STAA), the global leader in phakic IOLs, has scheduled its second quarter 2025 earnings conference call for August 6, 2025, at 4:30 p.m. ET. The company will release its financial results for the quarter ended June 27, 2025, after the market close on the same day.
STAAR Surgical specializes in Implantable Collamer® Lenses (EVO ICL™), having sold over 3 million ICLs across 75+ countries. The company's innovative EVO ICL™ product line offers vision correction through a minimally invasive procedure, eliminating or reducing dependency on glasses or contact lenses.
STAAR Surgical (NASDAQ: STAA), a leader in phakic IOLs, has appointed Deborah Andrews as Chief Financial Officer effective June 25, 2025. Andrews, who has been serving as Interim CFO since March 2025, previously held the CFO position from 2007-2013 and 2017-2020.
The company also announced the formation of a new Capital Stewardship Committee of the Board of Directors, to be chaired by Lilian Y. Zhou, focusing on financial strategies and capital allocation. As part of cost reduction efforts, STAAR is restructuring its investor relations function, with VP Brian Moore departing on June 27, 2025. The company is on track to achieve its targeted $225 million annual SG&A run rate ahead of schedule.
STAAR Surgical (NASDAQ: STAA) has announced a $30 million share repurchase program authorized by its Board of Directors. The company, a global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses, will execute the program over the next six months through various methods including open market purchases and structured agreements. As of March 28, 2025, STAAR had $222.8 million in cash and investments, no outstanding debt, and approximately 49.5 million shares outstanding. The company expects its cash position to remain above $140 million before generating cash in the latter half of 2025. The repurchase program demonstrates management's confidence in STAAR's future growth potential and commitment to shareholder value.
STAAR Surgical (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses, has scheduled its first quarter 2025 earnings release and conference call. The company will announce financial results for Q1 ending March 28, 2025, on Wednesday, May 7, 2025 after market close, followed by an earnings call at 5:15 p.m. ET.
STAAR Surgical specializes in implantable phakic intraocular lenses for vision correction, having sold over 3 million ICLs across 75+ countries. The company's EVO ICL™ product line offers vision correction through minimally invasive procedures, with operations spanning research, development, and manufacturing facilities in California and Switzerland.
STAAR Surgical (NASDAQ: STAA) announced significant leadership changes to optimize its organizational structure. Warren Foust has been promoted to President and Chief Operating Officer, expanding his oversight to include sales, manufacturing, operations, and additional departments. Dr. Magda Michna has been elevated to Chief Development Officer, taking on expanded responsibilities including R&D.
Key changes include:
- Deborah Andrews returns as Interim CFO, replacing Patrick F. Williams who is stepping down
- Keith Holliday retires as Chief Technology Officer
- Williams agrees to a three-month consulting period for transition
CEO Steve Farrell indicated these changes aim to drive revenue growth, improve cost structure, and enhance shareholder value. The company has already implemented measures to reduce long-term costs and plans to discuss additional growth opportunities during the first quarter earnings call.
STAAR Surgical Company (NASDAQ: STAA) announced a significant leadership transition, with Stephen C. Farrell appointed as President and CEO effective February 26, 2025. Farrell, currently serving as Lead Independent Director, will succeed Tom Frinzi, who will remain in an advisory role through January 2026.
The company also announced that Dr. Elizabeth Yeu has been elected as Board Chair, separating the roles of CEO and Board Chair. Farrell brings over 20 years of experience as both CEO and CFO of global healthcare businesses, most recently serving as CEO of Convey Health Solutions until February 2024.
The transition comes as STAAR, the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses, aims to navigate global macroeconomic challenges and drive market share gains in the refractive surgery market.